

**REMARKS**

Currently Claims 1-20 are pending. Claims 17-19 have been canceled. New claims 21-23 have been added. Support for these claims can be found at page 24, lines 33-35.

Claims 2-16 have been amended to place them in form appropriate to US practice, to reduce the filing fee by removing multiple dependencies, and/or to correct typographical errors. In claim 12, the recitations "or a salt or solvate thereof" have been deleted because the recitation of "a compound according to claim 1" in claim 12 includes compounds of formula (I) or a salt or solvate thereof. Claim 20 has been amended to insert formula (I) in the preamble and insert references to formula (I) in the recitations of the claims. The foregoing amendments do not narrow the claims and have not been made for purposes of patentability.


The specification has been amended to include a reference to related applications/claim of priority to the corresponding PCT application and foreign filed application.

Applicants have attached an Abstract on a separate sheet of paper as required by US practice.

Applicants respectfully submit that the present application is in condition for examination and respectfully request the early consideration thereof and the issuance of a Notice of Allowance forthwith.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Respectfully submitted:

  
J. Michael Strickland  
Attorney for Applicants  
Reg. No. 47,115

Date: Sept 1, 2004  
GlaxoSmithKline Inc.  
Corporate Intellectual Property  
Five Moore Drive, P.O. Box 13398


Application No. PCT/GB03/00876  
Attorney Docket No. PG4763USW

Research Triangle Park, NC 27709  
Tel. (919) 483-9024  
Fax: (919) 483-7988

Express Mail Label No.  
EV332145897US

**ABSTRACT**

Compounds of formula (I):



and uses of such compounds are described.